Podcasts about Cis

El día comienza con la noticia de la huelga médica prevista para enero, ahora incierta tras el abandono sindical de la negociación, y el suspenso histórico a la sanidad española según el CIS, con diez días de espera media para el médico de cabecera. Aumenta la firma de hipotecas en España, volviendo a niveles de 2010. La iniciativa Taxiluz lleva gratis la Navidad a ancianos en 17 ciudades. El programa '¡Buenos días, Javi y Mar!' entrega hoy sus premios en el teatro Capitol con Maldita Nerea y Pablo López. Oyentes comparten anécdotas cómicas con jefes. El colegio Madres Concepcionistas de Segovia gana el concurso de villancicos de '¡Buenos días, Javi y Mar!', donde los niños explican cómo deben ser los villancicos, prefiriendo el nacimiento de Jesús. La Fiscalía pide archivar la causa contra Íñigo Errejón. Los Oscar se verán gratis en YouTube desde 2029. "Arancel" es la palabra del año de FundéuRAE. Se explora la idea de un parque temático de Drácula en Rumanía. Aitana se sincera en ...

CADENA 100 anuncia villancicos de colegios como Irabia Izaga de Pamplona y EDUCREA de Villalvilla para mañana. El equipo de '¡Buenos días, Javi y Mar!' graba su villancico en Parque Warner. José Real informa del Plan BEO para gafas infantiles, la suspensión de la sanidad española según el CIS y el encarecimiento de productos navideños. La FundéuRAE elige 'arancel' como palabra del año. Celebran el cumpleaños de Alejandro Sanz con 'Jeroglíficos Auditivos' de sus éxitos. Esta tarde se entregan los premios '¡Buenos días, Javi y Mar! por un Mundo Mejor' en el Teatro Capitol, con actuaciones de Maldita Nerea y Pablo López. Raúl Incertis, médico de Médicos Sin Fronteras en Gaza, recibe un premio, compartiendo su experiencia. Reflexionan sobre la tendencia de buscar 'cómo perdonar' y la filosofía de Steve Jobs de decir 'gracias' en vez de 'lo siento'. Fernando Martín realiza su 'Encuesta absurda de CADENA 100'. El programa recuerda a artistas como Shakira o Adele que recuperaron su voz. El ...

This week, we find out about an NFL player, who depended on his speed, but didn't count on being out of the league, just as fast. He started acting strangely. He yelled at coaches & sucker punched a team mate. From there, he quickly goes down hill, off the field, with more strange behavior, which grows increasingly more violent, with arrest, after arrest. Was it mental illness, or head trauma?   Tell everyone that you're a better wide out than Calvin Johnson, climb a fence to try to get your impounded car back, and scare everyone around you, with increasingly erratic, and violent behavior with Titus Young!!   Check us out, every Tuesday! We will continue to bring you the biggest idiots in sports history!!   Hosted by James Pietragallo & Jimmie Whisman   Donate at... patreon.com/crimeinsports or with paypal.com using our email: crimeinsports@gmail.com Get all the CIS, STM & YSO merch at crimeinsports.threadless.com   Go to shutupandgivememurder.com for all things CIS, STM & YSO!!   Contact us on... instagram.com/smalltownmurder facebook.com/crimeinsports crimeinsports@gmail.com

Episode 1585: Cats In The Cradle

Episode 1584: Felt Cute

El CENTRA, el CIS andaluz, señala que si se celebraran elecciones a día de hoy el PP se quedaría a pocos pasos de la mayoría absoluta... por segunda vez... ya lo dijo el barómetro anterior. La encuesta pronostica otra leve bajada del voto de los andaluces al partido popular , que hoy obtendría entre 53 y 55 diputados. El PSOE tambien baja, se quedaría con entre 25 y 28 escaños. El que ganaría votos es Vox que podría conseguir ente 19 y 22 diputados Es la primera encuesta hecha completamente despues de que conociera la crisis de los cribados que hoy ha llevado a las afectadas a concentrarse de nuevo a las puertas del hospital Virgen del Rocío de Sevilla. Creen que el presidente de la Junta minimiza el problema al decir que solo un 1 % de las que sufrieron retraso en el cribado desarrollaron cáncer. Escuchar audio

Las negociaciones para evitar un adelanto electoral en Aragón fracasan entre el presidente Jorge Azcón y VOX; los comicios se prevén el 8 de febrero. El PSOE admite fallos en casos de acoso, respaldando a víctimas y expedientando a implicados. Alberto Núñez Feijóo exige la comparecencia de Pedro Sánchez en el Congreso por presuntos casos de corrupción, machismo y extorsión. La encuesta del CIS de diciembre da al PSOE 9 puntos de ventaja sobre el PP (31,4% vs 22,4%), con VOX en 17,6%. Pedro Sánchez es el líder mejor valorado y la vivienda, la principal preocupación nacional. Una experta en bomberos advierte del monóxido de carbono, recomendando limpiar chimeneas, revisar calefactores y usar detectores, además de ventilar. Insta a evitar sobrecargar enchufes y limpiar campanas extractoras; en Navidad, usar luces homologadas y apagarlas por la noche. Alumnos de Badajoz crean "ChemoBox" personalizadas para goteros de niños con cáncer, transformando la quimioterapia en "superpoderes". Esta ...

Ep. 190 features Irakli “Marcus” Davarashvili, Founder & CEO of Promofy, for a deep dive into the global rise of AI-powered gamification and how operators are rethinking loyalty, engagement, and retention. Hear him discuss: His 13-year journey across advertising, brand building, and iGaming leadership and how operational pain points at scale inspired him to build Promofy What Promofy is: an AI-driven, no-code gamification platform that lets operators launch loyalty systems, missions, sports predictors, prize drops, kiosks, and full-page engagement experiences in minutes How Promofy's rapid traction and product innovation led to winning “Launch of the Year” at the Starties, and why that recognition validated the team's vision and executio Why global operators misunderstand “gamification,” and how true gamified ecosystems differ from simple bonuses, cashbacks, and tournament The massive market shift away from bonus-led retention to personalized and behavior-driven engagemen Regional adoption trends across LATAM, Europe, Asia, CIS, and North America plus why gamification is becoming “must-have” instead of “nice-to-have How Promofy differentiates itself with AI design tools, content generators, sports prediction engines, casino loyalty, and a full library of mechanics that operators can test and optimiz The challenges and realities of fundraising as a first-time founder, why saying “yes” and “no” matter equally, and what kinds of investors Promofy is seeking today The transition from operator to entrepreneur expectations vs. reality, resilience, failure tolerance, and why agility is a survival skil Why 2026 will be a breakout year driven by global expansion, new product launches, and massive demand heading into the World Cup   Catch the video version of this episode here.   Learn more

La setmana horrible del PSOE amb la corrupci

Episode 1583: Aging Warhawks

Sterilization wrap is “not just a big blue plastic sheet.” According to Dr. Sade Brown, “It may look simple, but it is actually high-tech. Behind the scenes, there is a huge amount of science and engineering and testing that goes into it.” All of this work makes blue wrap an essential part of the sterilization system. In episode 140, host Jon Wood speaks with four members of the Kilmer Innovations in Packaging (KiiP) group: Amanda Benedict, Dr. Brown, Tanya Magaña and Tiffany Reece. Representing standards, manufacturing and healthcare end users, the panelists engage in a lively conversation about the engineering, development and proper use of sterilization wrap. They discuss ANSI/AAMI ST79, provide diverse perspectives on event-related sterility, and review educational opportunities for end users. Listen to learn more and gain strategies for how to collaborate with those outside the Sterile Processing department to protect sterility. ABOUT OUR GUESTS Kilmer Innovations in Packaging (KiiP) Inspired by a Kilmer Conference in 2019, the KiiP group works at “solving wicked problems in healthcare packaging.” Bringing together industry leaders, subject matter experts and end users, KiiP fosters collaboration with the goal of improving patient outcomes through innovations and education in healthcare packaging. Process This! episode 140 welcomes KiiP members Amanda Benedict, MA, SES-CSP, FSES, Vice President for Sterilization, AAMI; Sade Brown, PhD, R&D Engineer for Sterilization Products, O&M Halyard; Tanya Magaña, Supplier Excellence Engineering – Packaging, Solventum; and Tiffany Reece, CRCST, CIS, CHL, Clinical Assessment Specialist, Advantage Support Services, Inc. Earn CE Now

Imagine arriving at an event and knowing exactly what's on your plate—before you even step into the event venue. No guessing. No awkward questions. No fear of being left out. That's the vision behind Maritz 's new Event Menus. Designed to provide attendees a clear view of meal options—including key dietary restrictions and allergens—these digital menus help guests plan with confidence while making food an integrated part of the event experience. On next week's Eating at a Meeting Podcast LIVE, I'm talking with Emily Thibodeau, CMP, CITP, Vice President of Event Management, and Katie Rennegarbe, CIS , Manager of Technology Solution Design at Maritz. Together, we'll explore: ▶︎ How Event Menus are changing the way attendees interact with F&B ▶︎ Why visibility into dietary options builds trust and belonging ▶︎ How tech + hospitality can work hand-in-hand to create safer, more inclusive experiences ▶︎ What planners can learn from building accessibility into menu design from the start Emily brings her expertise in event management strategy, while Katie—deeply involved in the tech behind Event Menus—will share how Maritz brought this innovation to life. Food is one of the most human parts of an event. Let's talk about how digital solutions can make it safer, smarter, and more inclusive.

Guests Dr. Andrea Necchi, Dr. Ashish Kamat and host Dr. Davide Soldato discuss JCO article "End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer," focusing on the evolving treatment landscape of MIBC (muscle-invasive bladder cancer) and the need to properly design novel trials investigating non-operative management while including the incorporation of biomarkers and patient perspectives in clinical trials. TRANSCRIPT The disclosures for guests on this podcast can be found in the show notes. Dr. Davide Soldato: Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, medical oncologist at Ospedale San Martino in Genoa, Italy. Today we are joined by JCO authors Andrea Necchi, Associate Professor of Medical Oncology at University San Raffaele and Medical Oncology at Ospedale San Raffaele in Milan, Italy, and Ashish Kamat, Professor of Urologic Oncology and Cancer Research at University of Texas MD Anderson Cancer Center. Both Professor Necchi and Professor Kamat are internationally recognized experts in the field of genitourinary malignancy and particularly in bladder cancer. Today we will be discussing the article titled "Endpoints for the Next Generation Bladder-Sparing Perioperative Trials for Patients with Muscle-Invasive Bladder Cancer." So thank you for speaking with us, Professor Necchi and Professor Kamat. Dr. Andrea Necchi: Thank you, Davide, and thank you JCO for the opportunity. Dr. Ashish Kamat: Yeah, absolutely. It is a great honor and privilege to be discussing this very important article with you. So thank you for the invitation. Dr. Davide Soldato: The article that you just published in JCO reports the results of a consensus meeting that was held among experts in the field of genitourinary malignancy and particularly for bladder cancer. So the objective was really to define endpoints for a novel generation of trials among patients diagnosed with muscle-invasive bladder cancer. So my first question would be: what is the change in clinical practice and in clinical evidence that we have right now that prompted the start of such consensus in 2025? Dr. Andrea Necchi: So, we are living so many changes in the treatment paradigm of patients with muscle-invasive bladder cancer. In general, patients diagnosed with bladder cancer or urothelial cancer today, thanks to the advent of immunotherapy or immunotherapy combinations, and today thanks to the advent of novel antibody-drug conjugates like enfortumab vedotin in combination with immunotherapy that are actually changing the landscape of treatment of patients with metastatic disease and also are entering quite fast into the treatment paradigm of patients with organ-confined disease with a lot of clinical trials testing these combination therapies, neoadjuvantly or adjuvantly, before or after radical cystectomy. Having said that, by potentiating the efficacy of systemic therapy, an increasing number of patients that receive neoadjuvant therapy of any kind, at a certain point in time, result to have achieved a deep response to systemic therapy, evaluated radiologically with conventional imaging, CT scan or MRI, or with cystoscopy or with other urology-based techniques, urinary cytology, and so. And based on the fact that they achieve a complete response, so no residual viable disease after systemic therapy, they raise concern about the fact that they have to undergo surgery like radical cystectomy that is quite impactful for their quality of life and for the future of their lives after the surgery. So the point that the patients are raising, and the patients are raising this point, is primarily due to the efficacy of systemic therapy. And we have seen so many cases fortunately achieving a deep response. So the question about what to do with the patient that at a certain point, at the start with the commitment to radical cystectomy, but at a certain point in time change their mind towards something else if possible, depending on the fact that they have achieved a deep response, is something that is a question and is a need to which we have to provide data, information, and guidance in general to the patients. Dr. Davide Soldato: If we look at the population that the recommendations were formulated for, we are mainly speaking about patients who would be fit for cystectomy, and this is a very distinct population compared to those who are not fit for cystectomy, both from a medical oncology point of view but also from a urologic point of view in terms of surgery. So, can you explain a little bit to our listeners why you think that this distinction is critical and why you developed this recommendation especially for this population? Dr. Ashish Kamat: That is a very important distinction that you made. To build upon what Professor Necchi mentioned earlier, this question that we get from patients after neoadjuvant therapy or systemic therapy is not a new question. It has been something that they have been asking us for the last 20 or 30 years. "Do I really need to have my bladder taken out?" And patients who are especially not fit for surgery will sometimes say, "Do I need to have my bladder taken out? And if I cannot have my bladder taken out, am I going to just not have anything done?" Because the eligibility for radical cystectomy is also a moving target. Over the years with improvement in surgical technique, improvement in perioperative therapy, ERAS protocols, et cetera, it is really unusual for us to deny a patient the opportunity to have major surgery unless clearly they have very significant comorbid conditions. So I think this endeavor is more broadly encompassing of the patient population than what was evident in previous years. And I really want to give a shout out to Professor Necchi because what we did was, as part of the International Bladder Cancer Group and Professor Necchi is an integral part of the scientific advisory board, we broached this topic broadly during one of our discussions. And of course, Andrea always does this, he picks on a topic and then he says, "Okay, we need to discuss this really in detail," put together a multinational, multicenter collaborative group, but the driving force was our patients. Because our patients are constantly asking, "Do I need to lose my organ? Do I need to have radiation therapy?" which again, also, has a lot of side effects. So this was really to answer the question in today's day and age as to do we need to do local consolidation, and if so, in what way? It is not a new question, but we have newer therapies, newer technology, and better ways to answer this. So it is a much needed question that needs to be answered. And I think the distinction between non-surgical candidates and surgical candidates is a little bit blurred in today's day and age. Dr. Davide Soldato: What about the eligibility, for example, for cisplatin-based chemotherapy? Because I think that that is a very fundamental part of this type of strategy that we apply to patients with muscle-invasive bladder cancer. So we know that there are some caveats for proposing such treatment. And also this population was specifically defined inside this recommendation. Dr. Andrea Necchi: I think that the focus of our work is just to analyze what is happening after any type of systemic therapy the patient may get neoadjuvantly. So it is not actually a question of treatment eligibility or including cisplatin eligibility. This is an old question of today's practice and clinical trials. But regardless of what the patient received neoadjuvantly, the point that we have addressed in our consensus meeting was what to do next as a further step after systemic therapy or not. So basically we are- the consensus guidance includes all-comers, so patients to get any type of systemic therapy. So really non-selected based on specific features that determine a special eligibility to a special or a particular therapy. But an all-comer approach is always the winning approach for the translation to be in practice, an all-comer approach just focusing on what has happened after treatment and that we are assessing by the use of conventional imaging, MRI or CT, cystoscopy, urinary cytology, and trying to merge all together this information, all these features in a unique, shared, reliable definition of clinical complete response that could be used as a biomarker for the selection of newer therapies instead of pathological response that has been historically used, and maybe surrogate for the outcome, the long-term outcome and survival of these patients. Dr. Davide Soldato: A very specific point of the consensus was actually the definition of clinical complete response. As you were saying, this is actually a combination of several parameters including urinary cytology, the use of cross-sectional imaging, for example CT scan, but also the evaluation in cystoscopy of the bladder. Do you foresee any potential problems when applying this type of recommendation, not inside clinical trials, but in the context of routine clinical practice? Dr. Ashish Kamat: Absolutely. And that was the whole reason we had this consensus meeting. What happens nowadays in daily practice, and we see this every day at our center, we see patients referred to us. This definition or this sort of attempt to define clinical complete response is an ongoing issue. And urologists, medical oncologists, radiation oncologists are always looking to see, does my patient have a complete response? That definition and those paradigms have changed and evolved over the years. The FDA had a workshop many years ago looking at this very question. And it was to address the proposal that complete clinical response, which is a clinical definition, a clinical state, does this correlate with pathologic response? And with the technology and the systemic therapies we had then, the answer was 'no'. In fact, more patients got recurrent disease than did not get recurrent disease. And that is why, of course in the paper we mention the trials that looked at this question, the trials that evolved around this question. And I think the distinction between a clinical trial and daily practice is extremely important when we are looking at this definition per se. Because essentially what happens with this issue is that if the patient is not appropriately counseled, and if the physician does not do the appropriate clinical complete response assessment as Professor Necchi mentioned, right, cystoscopy, cytology, imaging, use of markers that are still in evolvement, we risk doing harm to the patient. So we caution in the paper too that this definition is not ready for prime time use. It is something that needs to be studied. It is a rigorous definition and currently we are recommending it for clinical trials. I am sure eventually it will trickle down into clinical practice, but that guidance was not the purpose of this consensus meeting. Dr. Davide Soldato: There are several parameters that are potentially evolving and could potentially enter inside of clinical practice. For example, you mentioned pelvic MRI and we have now very specific criteria, the VI-RADS criteria, we're able actually to diagnose and also to provide information. So along with these novel imaging techniques, we also know that there are novel biomarkers that could be explored, for example ctDNA and urinary DNA. So what I was wondering is, why were not these included inside the definition that you provide for clinical complete response? And do you think that, as we are designing these trials to potentially spare cystectomy for this patient, we should include these biomarkers very early so that we can actually provide better stratification for our patients and really propose this type of cystectomy-sparing strategy only to those where we are very confident that we have obtained a clinical complete response? Dr. Andrea Necchi: I would say you have just to wait. So a follow-up is ongoing and hard work is ongoing. At the time we met, at the time we established the meeting in mid-December last year, we had no information on the ctDNA data from major trials, with only a few exceptions. So we were just at the beginning of a story that was more than likely to change but still without numbers and without data from clinical trials. Now in just nine months or 10 months time, we have accumulated important data and newer data will be presented during just a few weeks and a few days regarding the ctDNA, circulating tumor DNA in particular, as a prognostic marker assessed baseline or assessed after neoadjuvant therapy. So the point is certainly well made and ctDNA is certainly well shaped to be incorporated in a future definition of clinical complete response. But you have to consider the fact that most of the data that we are accumulating related to ctDNA are about the post-cystectomy field or the metastatic field. So regarding neoadjuvant therapy, you know, we have neoadjuvant therapy in the context of bladder-sparing approach, basically we have no information. And the point that is emerging in our daily practice when using these biomarkers or in clinical trials, and the impression in general, is that it is a very strong biomarker associated with survival, but we absolutely do not know what is the performance of the test in the prediction of superficial bladder relapses, high-grade pTa relapse in the bladder that is left untouched in the patient. We are considering, and maybe it will be just a matter of further discussion, not just what is happening within the immediate endpoint of clinical CR, but also what is happening later with other survival endpoints. And for example, when looking at the type of events that we may see in this kind of bladder-sparing approaches, most of the events, also in the trials that have been published including the RETAIN study published in JCO, most of the events are related to superficial high-grade superficial non-muscle invasive relapses. So the ability to predict these types of events with ctDNA is completely unknown. Maybe, maybe other liquid biomarkers like urinary tumor DNA, utDNA, could be a bit better shaped in the prediction of this kind of events, you know. But we have still to build the story. So the question is good. The answer is yes, we will likely, more than likely incorporate liquid biomarkers in the definition, but we have to wait at least more data and more robust data in order to translate this information in routine practice, you know. Another consensus meeting is organized by IBCG and the same folks for November. This meeting will be primarily focused on the liquid biomarkers, the interpretation and use and approval and so of liquid biomarkers including bladder cancer. And we will likely be able to address all these, most of these open issues, so most of these points in the next meetings. Dr. Davide Soldato: In the consensus you say that probably clinical complete response is now ready to be included in early phase trials, so actually to test what is the efficacy of the regimens that is being evaluated inside of these trials. But you actually do very in-depth work of defining what are the most appropriate endpoints for later phase trials. So to be very specific, the phase three registrational trials that bring new regimens inside of this space. So I just wanted to hear a little bit about what was the definition for event-free survival, which you define as the most appropriate one for this type of trials. And as you were mentioning before, Professor Necchi, there is a very specific interest on the type of events that we observe, especially when we look at these superficial relapses inside of the bladder. So was this a very urgent matter of debate as we define which type of events should actually trigger event-free survival? And did you make a very thoughtful decision about why using this type of endpoint instead of others, for example metastasis-free survival? Dr. Ashish Kamat: Yeah, this was a matter of intense debate as you might imagine. And again, this is a moving target. So as Professor Necchi mentioned, we tend to partner with each other, our organizations, on having definitions of clinical complete response, biomarker, retreats, and then using that as a marker, and you might imagine this definition of what is appropriate event-free survival, what events matter to the patient, is something we have been talking about for two years. It was not just something that came up at the retreat. But at the retreat there was intense discussion. One of the things that we talked about was bladder-intact event-free survival because we are trying to spare the patient's bladder. And do we count bladder-intact event-free survival as something that is relevant? The patient advocates absolutely liked that, right? They wanted that. But then we also learned from some of the studies, for example from the RETAIN study, that the non-muscle invasive recurrences can actually lead to metastatic disease. It is not as benign when you have a patient with muscle-invasive bladder cancer that then develops a non-invasive tumor because maybe there is cancer growing underneath the surface that we don't detect when we look in the bladder. So a lot of those discussions were held, debated. It was a consensus. I have to say it was not 100% agreement on that particular definition, but it was broad consensus. And Andrea, do you want to clarify a little bit as to how we came about that consensus? Because I think this is a very important point we need to make. Dr. Andrea Necchi: We focused on a bit different definition of BI-EFS, Bladder-Intact Event-Free survival. Just stating EFS as an all-inclusive parameter including all type of high-grade relapse or progression or death that may happen to the patient. So that we were counting high-grade pTa, pT1, CIS relapses to the bladder and of course more deeper involvement in the muscle layer and so, and metastatic disease as a relapse. But the point is that as compared to the classical bladder-intact EFS definition of chemoradiation bladder-sparing approaches that is including muscle-invasive relapses only or death as events, we tried to be as inclusive as possible in order to be as much conservative as possible and to raise as higher the bar as possible for the success. And this is actually what the patients are asking us. So they are asking, "Okay, I can save my bladder, sparing radical cystectomy, but at which cost?" So in order to provide an answer, we have to be very, very cautious and be on the right shape, on the right position to say, "Okay, we have accomplished the most, the safest points, you know, by which you can proceed with the bladder-sparing." This is the first point. The other point is related to the MFS, metastasis-free survival that you have mentioned. For sure, it was recognized as a very important point for sure. But in the discussion was clear that our focus was in saving patients, curing the patient, and saving the bladder. Any single event, superficial event that may occur in the bladder-saving approaches of this kind may expose the patient to an extra risk of developing distant metastases, as it happened for example in the RETAIN study. So EFS defined as we have agreed and published, is actually a way of including or anticipating in a safest position the MFS. Because most or if not the entirety of the events of metastasis development in patients undergoing bladder-sparing after neoadjuvant systemic therapy were preceded by a superficial phase of disease relapse, you know. So I remember very, very few, or we can count just on the finger of one hand, the cases that have been reported in the literature developing de novo metastatic disease in the similar bladder-sparing approaches, in particular when using a maintenance immunotherapy strategy, you know, after they reach TURBT. So this is the reason why with all the limitation that Ashish has mentioned, with all the uncertainties that are still there, the nervousness that is still there, EFS, as defined in the protocol, as put in the paper, is to us at the moment is the safest way to use a primary endpoint in potentially registration trials of this kind with perioperative systemic therapy and response-adapted surgery. Dr. Ashish Kamat: And David, just to be absolutely clear for our listeners, right, so what was the event-free survival that we defined? Essentially it was a very inclusive definition. Event was defined as high-grade tumor persistence, recurrence, or progression during or after perioperative therapy, and receipt of any additional standard of care treatment including radical cystectomy, radiotherapy or even intravesical therapy. So this was done at the behest of our patient advocates because we really wanted to make a very robust definition that could be utilized appropriately as an adequate primary endpoint for both early and late phase bladder preservation trials. Dr. Davide Soldato: I think that it really highlights one of the points that I liked the most about this consensus is that it really incorporated the patient vision and a sort of shared decision making process when we are deciding how we want to design these trials that will explore this bladder-sparing surgery. And Professor Necchi mentioned something that I think will be also a very interesting question for trials that will be developed considering the activity of this combination that we are seeing right now, which is maintenance. Because right now our approach in the few cases where patients do not do any type of treatments after an induction with neoadjuvant treatments is basically represented by observation. So I was wondering if you think that the field will actually evolve to a sort of maintenance strategy even in patients that will achieve a complete clinical response? Dr. Andrea Necchi: We just mentioned briefly in the paper, this is a very important point that was touched during the discussion, and in particular was raised and discussed by FDA people participating in the meeting. And when looking at the data from the trials that were available and are still available thus far, we could provide a suggestion that maintenance immune therapy is the preferred approach in this kind of approach as it currently stands, as the data currently stand. Because the cleanest data towards the successful part of this journey is related to the studies that provided a kind of maintenance therapy, like the study with nivolumab or the RETAIN-2 study with maintenance immune therapy instead of RETAIN study that was just stopping treatment until surgery with MVAC chemotherapy. So in general the impression is that maintenance therapy may help in reducing the type of events, including the events that we incorporate in the EFS definition that we mentioned in the paper. The point that you mentioned is very important because on the other side we have a problem, a big problem of affordability and cost of the treatment. The de-escalation trials are an urgent need and represent a call for the studies. Unfortunately, as you mentioned, this is something that moves beyond the possibilities of this type of consensus because we don't have data and we have to accumulate data from clinical trials prior to saying, "Okay, certain patients could de-escalate therapy and stop therapy and some other not." So we are still at the very beginning. So we can do- we can discuss about this in the radical cystectomy paradigm but not in the bladder-sparing paradigm, you know. But this is for sure a point, a discussion point that will be taken, pretty well taken in one year or two year projection. Dr. Davide Soldato: I was wondering if in the consensus, considering that patient advocates and patient associations were also involved, did you decide to actually suggest the inclusion of patient-reported outcomes or the evaluation of shared decision-making in the development of this trial really as endpoints that should matter as much or as much as possible as event-free survival and clinical complete response? Dr. Ashish Kamat: Oh yeah, absolutely. We had patient advocates, we had the World Bladder Cancer Patient Coalition, Bladder Cancer Advocacy Network, patient representatives. And we always consider this. Shared decision-making is actually the impetus behind why these efforts have been launched, right? So it is the shared decision-making that is very, very important. It is the driving force behind what we do. And it is worth noting, for example, for the design of such studies, regulatory agencies consider response-based endpoints or overall survival as primary endpoints. But the patient advocates consider quality of life to be just as important, if not more important sometimes than overall survival numbers. Because patient advocates will say, "Well if I live longer but I'm miserable living longer, yes that works for regulatory agencies but doesn't work for us." So PROs clearly are very, very important. And, in fact, we just literally had a meeting in Houston, the IBCG meeting where PROs were a main point of what we discussed. So incorporating PROs in everything we do, not just this but everything we do, Dr. Necchi, myself, everybody involved in these fields realizes it is very, very important. So absolutely. Dr. Davide Soldato: I want to thank again Professor Necchi and Professor Kamat for joining us today. Dr. Andrea Necchi: Thank you. Dr. Ashish Kamat: It is our pleasure. Dr. Davide Soldato: Thanks again and we appreciate you sharing more on your JCO article titled "Endpoints for the Next Generation Bladder-Sparing Perioperative Trials for Patients with Muscle-Invasive Bladder Cancer." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcast. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

In Episode 165 of Cybersecurity Where You Are, Tony Sager sits down with Valecia Stocchetti, Senior Cybersecurity Engineer at the Center for Internet Security® (CIS®), and Charity Otwell, Director of Critical Security Controls at CIS. Together, they take an in-depth look at implementing the CIS Critical Security Controls® (CIS Controls®), including what you need to know to begin your own CIS Controls implementation efforts.Here are some highlights from our episode:00:53. Introductions to Valecia and Charity02:48. How the CIS Controls ecosystem answers the deeper question of how to implement06:42. The importance of clear strategy, business priorities, and a realistic timeline09:56. How the CIS Community Defense Model (CDM) clarifies cyber defense priorities13:01. The use of calculations around costing to make a security program achievable15:31. Bringing IT and the Board of Directors together through governance20:36. "Herding cats" as a metaphor for navigating different compliance frameworks23:17. Why one prescriptive ask per CIS Safeguard starts cybersecurity workflows25:30. "Why" vs. "how" communication, accountability, staffing, budget, and continuous improvement as keys to success for CIS Controls implementation42:03. CIS Controls Assessment Specification as an answer to implementation subjectivity47:21. Parting thoughts around team effort, change, and CIS Controls AccreditationResourcesCloud Companion Guide for CIS Controls v8.1CIS Community Defense Model 2.0The Cost of Cyber Defense CIS Controls IG1Episode 132: Day One, Step One, Dollar One for CybersecurityPolicy TemplatesEpisode 107: Continuous Improvement via Secure by DesignReasonable Cybersecurity GuideCIS Controls ResourcesCIS Controls Assessment SpecificationEpisode 156: How CIS Uses CIS Products and ServicesCIS Controls AccreditationControls AccreditationEpisode 102: The Sporty Rigor of CIS Controls AccreditationIf you have some feedback or an idea for an upcoming episode of Cybersecurity Where You Are, let us know by emailing podcast@cisecurity.org.

En el 50 aniversario del Instituto Alemán, Hugo Luengo reflexiona sobre cómo la historia se repite cíclicamente como farsa. El autor establece una comparación entre el nacionalsocialismo del Partido Nacionalista Obrero Alemán, que ocupó el poder en Alemania entre 1933 y 1945, y ciertas dinámicas políticas actuales en España. Aquel régimen totalitario, que causó millones de muertes, se desarrolló siguiendo los principios de propaganda de Joseph Goebbels, ministro de Ilustración Pública y Propaganda de Hitler. Luengo identifica ocho principios que considera presentes en el discurso político contemporáneo. El primero es el principio de orquestación, donde la propaganda se limita a un pequeño número de ideas que se repiten incansablemente, convirtiendo la mentira en verdad mediante la repetición constante. El segundo es el principio de silenciación, que busca acallar las cuestiones incómodas mediante el control de medios de comunicación, incluyendo el INE, el CIS de Tezanos, Radio Televisión Española y otros organismos. El tercer principio es el de vulgarización, adaptando la propaganda al nivel intelectual menos exigente de las masas. El cuarto habla de la renovación constante de informaciones y argumentos para mantener al público interesado. El quinto es el método de contagio, que consiste en individualizar al adversario y construir el sistema político como suma de individuos, cuestionando la actual configuración autonómica de España. El sexto principio es el de trasposición, que implica cargar sobre el adversario los propios errores y responder al ataque con el ataque. El séptimo es el de verosimilitud, construyendo argumentos a partir de fuentes diversas y fragmentarias. Finalmente, el octavo principio es el de transfusión, que opera a partir de un sustrato preexistente de odios y prejuicios para reforzar actitudes primitivas, como ocurrió en la Guerra Civil española. El autor concluye señalando que el PSOE se ha deslizado hacia un socialcomunismo que requiere convencer a los ciudadanos de los males del muro que separa a la sociedad civil de la verdad, la libertad y la economía.

This week, we finish this epic tale with Billy, trying to live a peaceful "retirement", on a large farm property in upstate New York. It seems like the perfect place, but Billy is bored, and plotting his managerial return to the Yankees. This boredom causes Billy to drink, and fight with his wife, leaving broken glass, and melted ice cream, in their wake. We finally end with Billy's sudden death, and court cases about the details. Even in death, there is drama for Billy!   Buy yourself a 150 acre farm & start feeding the animals, get bored with your farm work, and drink away the cold nights, have even your death be controversial, and of course, alcohol fueled with Billy Martin - Part 11!!   Check us out, every Tuesday! We will continue to bring you the biggest idiots in sports history!!   Hosted by James Pietragallo & Jimmie Whisman   Donate at... patreon.com/crimeinsports or with paypal.com using our email: crimeinsports@gmail.com Get all the CIS, STM & YSO merch at crimeinsports.threadless.com   Go to shutupandgivememurder.com for all things CIS, STM & YSO!!   Contact us on... instagram.com/smalltownmurder facebook.com/crimeinsports crimeinsports@gmail.com

Episode 1582: Observe And Report

There is no one-size-fits-all method to building and growing a successfull custom integration business. That said, from what Matt Bernath, President of Vital, has seen in his years of working with and coaching CIs, there are many similarities between a company stuck in that $1-2 million range, and those that have gotten over the hump and scaled their business. At CEDIA Expo, Vital was our booth neighbor, and we sat down with Bernath to talk about those challenges and so much more. https://youtu.be/2tatpXJudII?si=t6pXa-2BzTRkt9xd

Episode 1581: Twisted

Episode 1580: Flagrant Simp

https://revengeofthecis.locals.com/

This week, we pick up with Billy being arrested, on the front lawn of his girlfriend's house. He's  rehired as the Yankee manager, only to be fired, at the end of the season. But dont worry, he'll be hired & fired, again! He also gets in a four part brawl with one of his own pitchers, and is attacked in a strip club bathroom. He's divorced, remarried, and looking for how to deal with life, when not managing the Yankees!   Fight with your 27 years younger starting pitcher, get sued by bothe the IRS & your soon to be ex-wife, and get fired a couple more times with Billy Martin - Part 10!! Check us out, every Tuesday! We will continue to bring you the biggest idiots in sports history!!   Hosted by James Pietragallo & Jimmie Whisman   Donate at... patreon.com/crimeinsports or with paypal.com using our email: crimeinsports@gmail.com Get all the CIS, STM & YSO merch at crimeinsports.threadless.com   Go to shutupandgivememurder.com for all things CIS, STM & YSO!!   Contact us on... instagram.com/smalltownmurder facebook.com/crimeinsports crimeinsports@gmail.com

Episode 1579: Fashion

Episode 1578: Stanger Things

https://revengeofthecis.locals.com/newsfeed    

In Episode 163 of Cybersecurity Where You Are, Sean Atkinson and Tony Sager sit down with Brock Boggs, Director of Technology at Cityscape Schools, and Maureen Kunac, Senior Product Manager at the Center for Internet Security® (CIS®). They dive into the realities and challenges of K-12 cybersecurity, including limited budgets, small teams, and growing threats.Brock shares how a ransomware incident at a neighboring school district and new state requirements pushed his district to take K-12 cybersecurity more seriously. He explains how CIS SecureSuite® tools gave him a clear starting point and helped him transform panic into progress. Maureen highlights how CIS continues to adapt its cybersecurity solutions for K-12 schools and why simplicity matters when resources are tight.Here are some highlights from our episode:00:47. Introductions to Brock and Maureen02:50. What prompted Cityscape Schools to prioritize cybersecurity and how Brock found CIS11:50. The importance of simplicity in making K-12 cybersecurity practical12:39. A collaborative journey of helping Brock get comfortable learning about cybersecurity22:52. A look back at Cityscape Schools pivoted to remote education during COVID-1934:20. Brock's advice for other school districts to get started with a cybersecurity programResourcesFormalizing K-12 Cybersecurity Policies in Less TimeHow to Plan a Cybersecurity Roadmap in 4 Steps2025 K-12 State of Cybersecurity Report: Where Education Meets Community ResilienceEpisode 142: SLTTs and Their Nuanced Cybersecurity Needs25 Years of Creating Confidence in the Connected WorldIf you have some feedback or an idea for an upcoming episode of Cybersecurity Where You Are, let us know by emailing podcast@cisecurity.org.

This week, we find Billy fired, again. He's also living a double life, by getting married to his teenaged girlfriend, but also carrying on an affair, right out in the open, with an attractive photographer. He also gets another job, and is fired. He gets in several fights, including a certain marshmallow salesman, and several others, all while the IRS breathes down his neck. Oh, also gets another job. And is fired. Can Billy ever learn to relax???   Hook up with a sexy photographer, while your wife waits at home, get fired 3 times in 4 years, "quit drinking" by only drinking beer with Billy Martin - Part 9!!   Check us out, every Tuesday! We will continue to bring you the biggest idiots in sports history!!   Hosted by James Pietragallo & Jimmie Whisman   Donate at... patreon.com/crimeinsports or with paypal.com using our email: crimeinsports@gmail.com Get all the CIS, STM & YSO merch at crimeinsports.threadless.com   Go to shutupandgivememurder.com for all things CIS, STM & YSO!!   Contact us on... instagram.com/smalltownmurder facebook.com/crimeinsports crimeinsports@gmail.com

Episode 1577: Jive Turkeys

Con Víctor Lapuente, Josep Ramoneda y Elisa de la Nuez. La persona que el Gobierno propone como sustituta de Álvaro García Ortiz al frente de la fiscalía general del estado es Teresa Peramato, quien tiene una amplia trayectoria en la lucha contra la violencia de género. Su propuesta tendrá que pasar por el consejo de ministros. El CEO, el CIS catalán, pronostica el auge de la extrema derecha. Aliança Catalana alcanzaría a Junts como tercera fuerza con 20 escaños. Además, la Audiencia Nacional no exime de juicio a Jordi Pujol a pesar de los informes médicos. Tendrá que asistir por videoconferencia. La defensa pide la nulidad de la causa al proceder -dicen- de las cloacas del Estado.

Episode 1576: The Country Of Origin

https://revengeofthecis.locals.com/    

We dissect Labor's proposed environmental reforms with the help of Ashurst legal expert Jeff Lynn. Plus: News of the week, and is the CIS working?

Learn about vein disease and the treatment options available at CIS with interventional cardiologist and vascular specialist Dr. Amit Amin.Visit www.cardio.com for more information or to schedule an appointment with one of our providers.

Episode 1575: Fine People (podcast)

In this episode, Charles Carillo sits down with Ian Colville, Founder & Managing Partner of Carpathian Capital Management, to break down one of the most unique paths into U.S. real estate investing, starting in emerging markets, navigating international crises, and ultimately building a multi-million-dollar residential development platform in the United States. Ian shares how a decade in Russia and the CIS shaped his crisis-investing mindset, why housing became one of the most undervalued hard assets after 2008, and how his firm evolved from buying single-family homes to private lending and large-scale land development across the country. If you want to understand how professionals evaluate markets, manage risk, and find opportunities in today's housing shortage, this episode is a must-watch.   What You'll Learn in This Episode: How emerging market experience helped Ian identify U.S. housing opportunities Why crisis environments often create the highest-return investments The shift from distressed single-family homes to development finance How land scarcity became the biggest bottleneck in new construction The importance of “months of supply” in choosing real estate markets How foreign investors view U.S. real estate today Key mistakes real estate investors make and how to avoid them Learn More About Ian Here: Carpathian Capital Management - https://carpathiancapital.com/ Connect with the Global Investors Show, Charles Carillo and Harborside Partners: ◾ Setup a FREE 30 Minute Strategy Call with Charles: http://ScheduleCharles.com ◾ Learn How To Invest In Real Estate: https://www.SyndicationSuperstars.com/  ◾ FREE Passive Investing Guide: http://www.HSPguide.com ◾ Join Our Weekly Email Newsletter: http://www.HSPsignup.com ◾ Passively Invest in Real Estate: http://www.InvestHSP.com ◾ Global Investors Web Page: http://GlobalInvestorsPodcast.com/

https://revengeofthecis.locals.com/  

La Fiscalía Anticorrupción solicita 24 años de cárcel para el exministro Ábalos por delitos de organización criminal, cohecho, tráfico de influencias y malversación, mientras Santos Cerdán obtiene la libertad provisional. Se especula sobre el conocimiento del presidente Pedro Sánchez en la trama. La UCO desvela mensajes que implican al PNV pidiendo cargos a cambio de apoyo político. En el plano internacional, un ataque ruso en Ternopil, Ucrania, causa 25 muertos y más de 90 heridos, y la Comisión Europea propone la libre circulación de ejércitos en la UE. En la política nacional, Pérez Yorca presenta su candidatura a la Generalitat Valenciana buscando el apoyo de Vox, y el CIS de Tezanos mantiene al PSOE como la fuerza más votada. El Gobierno propone una subida salarial del 10% para funcionarios, rechazada por sindicatos. El Congreso convalida el real decreto de la Ley ELA, incluyendo ayudas significativas. La natalidad en España registra un nuevo mínimo histórico, y se detiene a un ...

This week, we catch up to a triumphant Billy, as he basks in the glow of World Series victory. This, of course, leads him to brutally pummel a reporter, who dared ask a question about a recent Yankee trade. He is forced to resign, only to be rehired, within 2 months. He fights with players, reporters, and one, very angry team owner. He also finds love, with a young lady, who many people believe is only 16 years old!   Beat a reporter into a bloody heap, over minor infractions, be forced to resign, the year after you won the World Series, and continue to cause a scene, and drink heavily, but never "overdrink" with Billy Martin - Part 8!!   Check us out, every Tuesday! We will continue to bring you the biggest idiots in sports history!!   Hosted by James Pietragallo & Jimmie Whisman   Donate at... patreon.com/crimeinsports or with paypal.com using our email: crimeinsports@gmail.com Get all the CIS, STM & YSO merch at crimeinsports.threadless.com   Go to shutupandgivememurder.com for all things CIS, STM & YSO!!   Contact us on... instagram.com/smalltownmurder facebook.com/crimeinsports crimeinsports@gmail.com

Episode 1574: Warby Puker

Episode 1573: H1B Dreams

Episode 1572: Oh Bother

Comedian James Tom spent years identifying as a lesbian enby, but it took a Fire Island orgy and a twink in a Versace speedo to help him realize he was actually a gay guy. James has been mining his experiences for hilarious stand-up material ever since. In this episode, James stops by to tell Gabe and Chris side-splitting stories of sexual aha moments and misadventures alike. He also offers tons of helpful advice to trans and cis queers who “just wanna fuck” -- including Chris and Gabe! Want to know what cis guys should absolutely NOT say when hooking up with trans guys? This episode’s for you! Follow Sniffies' Cruising Confessions: cruisingconfessions.com Try Sniffies: sniffies.com Follow Sniffies on Social: Instagram: instagram.com/sniffiesapp X: x.com/sniffiesapp TikTik: tiktok.com/@sniffiesapp Follow the hosts: Gabe Gonzalez: instagram.com/gaybonez Chris Patterson-Rosso: instagram.com/cprgivesyoulife Guests featured in this episode: James Tom: https://www.instagram.com/jamestomxo/See omnystudio.com/listener for privacy information.

FULL SHOW https://revengeofthecis.locals.com/newsfeed    

This week, we find Billy Martin at the brink of a triumphant season, that would cement his managerial legacy. The problem is, there's going to be much drama, in the process. From fighting, in the dugout, on national televison, with his star player, to fighting with the team owner, at 2 am, after everyone has had a few cocktails, to causing a scene, by fighting with his wife, during a celebration... Billy is starting to unravel! All of this while NYC expeciences a huge blackout, and The Son of Sam runs rampant!!   Fight your star player, in front of the world, challenge someone who says they have a 160 IQ, and drink, cheat on your wife, and begin to fall apart with Billy Martin - Part 7!!   Check us out, every Tuesday! We will continue to bring you the biggest idiots in sports history!!   Hosted by James Pietragallo & Jimmie Whisman   Donate at... patreon.com/crimeinsports or with paypal.com using our email: crimeinsports@gmail.com Get all the CIS, STM & YSO merch at crimeinsports.threadless.com   Go to shutupandgivememurder.com for all things CIS, STM & YSO!!   Contact us on... instagram.com/smalltownmurder facebook.com/crimeinsports crimeinsports@gmail.com

Episode 1571: Ka$h Grab

This week, Ben Appel joins me to talk about his new book, Cis White Gay: The Making of a Gender Heretic, a memoir about leaving one kind of cult only to stumble into another. Raised in a rigid Christian community, Ben found refuge in the gay rights movement and, later, the Ivy League—until "allyship" started to look less like solidarity and more like a loyalty oath.   We discuss   • Why he chose the deliberately provocative title Cis, White, Gay — and what reactions revealed about current identity politics. • How queer "community" has become increasingly moralized, hierarchical, and policed — and what gets lost when dissent is framed as betrayal. • The difference between taste and taboo — and how aesthetic preferences are now treated as political statements. • Why "representation" has replaced excellence as the highest cultural virtue. • How literary gatekeeping operates today — from publishers and prize committees to informal online watchdogs. • The loneliness of ideological nonconformity in queer and creative circles. • The professional and social costs of questioning orthodoxy — including lost friendships, lost opportunities, and subtle blacklisting. Guest Bio: Ben Appel is a writer and commentator whose memoir, Cis White Gay, traces his path from a strict Christian sect to progressive activism—and his break with movement orthodoxy; he's written for outlets like Newsweek, UnHerd, and more, and publishes on Substack.    Become a paying subscriber to The Unspeakeasy and get lots of perks, including access to monthly hangouts for Founding Members. https://www.theunspeakablepodcast.com/    I'm teaching a Zoom writing workshop in Memoir and Personal Essay, Jan 6 through Feb 24, 2026. Apply by Dec 5. https://www.theunspeakablepodcast.com/p/next-writing-course-starts-jan-6    The Unspeakeasy 2026 retreat schedule has been announced! https://theunspeakeasy.com/retreats  Order my book, The Catastrophe Hour: Selected Essays, on Amazon or directly from the publisher https://www.nyrb.com/products/the-catastrophe-hour.

Episode 1570: Can’t Find A Fetterman

This week, we take a break from our Billy Martin series, to bring you a bonus episode, that is more relevant than ever, right now. Mixing otherwordly talent, with the black cloud of gambling allegations, hanging over head, makes this as crazy a story as we've talked about. Did the greatest talent, in the game of baseball, the modern day face of game, actually commit acts that should have him banned for life, while everyone is happy to blame a lowly interpreter, for everything??? We look into the scandal that surrounded Shohei Ohtani!!   This episode was recorded in April of 2024, and put out as part of our Patreon bonus feed. To get all the bonus eps & ad free versions of all of our podcasts, go to patreon.com/crimeinsports   Check us out, every Tuesday! We will continue to bring you the biggest idiots in sports history!!   Hosted by James Pietragallo & Jimmie Whisman   Donate at... patreon.com/crimeinsports or with paypal.com using our email: crimeinsports@gmail.com Get all the CIS, STM & YSO merch at crimeinsports.threadless.com   Go to shutupandgivememurder.com for all things CIS, STM & YSO!!   Contact us on... instagram.com/smalltownmurder facebook.com/crimeinsports crimeinsports@gmail.com

This week, we catch up with Billy, as he is again fired, despite being the league's Manager of the Year. He fights, more & more, with his celebrity getting him out of multiple arrests. But his celebrity doesn't help his attempted cocaine mule of a daughter. He lands his dream gig, as manager of the New York Yankees, only to almost be fired for talking back to the owner. Billy will never learn! Get fired, even though you're the AL Manager of the Year, call Frank Sinatra & Henry Kissenger to try to get your daughter out of trouble, and start fighting with your new team's owner with Billy Martin - Part 6!! Check us out, every Tuesday! We will continue to bring you the biggest idiots in sports history!! Hosted by James Pietragallo & Jimmie Whisman Donate at... patreon.com/crimeinsports or with paypal.com using our email: crimeinsports@gmail.com Get all the CIS, STM & YSO merch at crimeinsports.threadless.com Go to shutupandgivememurder.com for all things CIS, STM & YSO!! Contact us on... instagram.com/smalltownmurder facebook.com/crimeinsports crimeinsports@gmail.com

This week, we follow Billy's exploits, as his teams perform wonderfully, on the field, but it's still not enough to keep him from getting repeatedly fired. Why? Because he fights with team owners, opposing players/managers/fans & umpires. He even beats one of his own players, so badly, that they have to be hospitalized for 20 stitches to their face! Then, he gets arrested for actually doing something admirable! Wild as always!   Take a team from nearly last place, to winning their division... and get fired, lead another team back from the dead... and get fired, then quickly get another job, despite your reputation with Billy Martin - Part 5!!   Check us out, every Tuesday! We will continue to bring you the biggest idiots in sports history!!   Hosted by James Pietragallo & Jimmie Whisman   Donate at... patreon.com/crimeinsports or with paypal.com using our email: crimeinsports@gmail.com Get all the CIS, STM & YSO merch at crimeinsports.threadless.com   Go to shutupandgivememurder.com for all things CIS, STM & YSO!!   Contact us on... instagram.com/smalltownmurder facebook.com/crimeinsports crimeinsports@gmail.com